What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Asthma
- Disease
The scientist’s investigation covers issues in COPD, Internal medicine, Asthma, Physical therapy and Immunology.
He combines subjects such as Respiratory disease, Pulmonary disease, Intensive care medicine, Disease and Spirometry with his study of COPD.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Placebo, Endocrinology and Sputum.
His Asthma study incorporates themes from Global health, Health care and Family medicine.
The study incorporates disciplines such as Prospective cohort study, Clinical trial, Severity of illness and MEDLINE in addition to Physical therapy.
In his work, Chlamydia, Pneumonia, Serology, Bronchial hyperreactivity and Asthma copd overlap is strongly intertwined with Airway obstruction, which is a subfield of Immunology.
His most cited work include:
- Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) (3245 citations)
- Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study (894 citations)
- Burden and clinical features of chronic obstructive pulmonary disease (COPD). (805 citations)
What are the main themes of his work throughout his whole career to date?
Klaus F. Rabe focuses on Internal medicine, COPD, Asthma, Immunology and Intensive care medicine.
His work investigates the relationship between Internal medicine and topics such as Placebo that intersect with problems in Randomized controlled trial.
His study looks at the relationship between COPD and fields such as Anesthesia, as well as how they intersect with chemical problems.
His work in the fields of Asthma, such as Dupilumab, intersects with other areas such as In patient.
His Immunology research includes elements of Sputum and Lung.
Klaus F. Rabe has included themes like Disease and MEDLINE in his Intensive care medicine study.
He most often published in these fields:
- Internal medicine (34.47%)
- COPD (34.00%)
- Asthma (21.17%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (34.47%)
- Asthma (21.17%)
- COPD (34.00%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Asthma, COPD, Budesonide and Metered-dose inhaler are his primary areas of study.
His studies deal with areas such as Gastroenterology and Placebo as well as Internal medicine.
Asthma is the subject of his research, which falls under Immunology.
He interconnects Megakaryocyte and breakpoint cluster region in the investigation of issues within Immunology.
His Obstructive lung disease study, which is part of a larger body of work in COPD, is frequently linked to Tumor necrosis factor receptor 2, bridging the gap between disciplines.
Within one scientific family, Klaus F. Rabe focuses on topics pertaining to Glycopyrrolate under Budesonide, and may sometimes address concerns connected to Formoterol Fumarate and Pulmonary disease.
Between 2019 and 2021, his most popular works were:
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD (48 citations)
- Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19. (24 citations)
- Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. (13 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
Klaus F. Rabe spends much of his time researching Internal medicine, Asthma, COPD, Placebo and Dupilumab.
His Internal medicine study frequently links to related topics such as Gastroenterology.
His Asthma research incorporates themes from Body mass index, Vital capacity, microRNA, Cell biology and Cohort.
His COPD research includes themes of Exacerbation, Metered-dose inhaler, Bronchodilator and Hazard ratio.
In his study, which falls under the umbrella issue of Dupilumab, Corticosteroid, Airway obstruction and Exhaled nitric oxide is strongly linked to FEV1/FVC ratio.
His work deals with themes such as Glucocorticoid, Inhalation, Randomized controlled trial and Muscarinic antagonist, which intersect with Pulmonary disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
